Last month we launched our first PEGS Virtual Interactive Global Summit with more than 300 participants from 15 countries logging in to hear cutting-edge science.
Scientific presentations are available on-demand and registrants may access this content anytime for up to 12 months following the event.
We’re excited to bring you an even more dynamic experience this summer when our PEGS Boston Summit goes virtual for a 5-day immersive experience on Aug. 31- Sept. 4. To learn more CLICK HERE.
Access Quality, Targeted Programming for Protein Science and Biotherapeutics Discovery
TUESDAY
Week 1: June 2
• Display Technologies for Rapid Antibody Discovery
Week 2: June 9
• Antibodies to Combat Pandemic Viruses
Week 3: June 16
• Engineering Bispecific Antibodies
Week 4: June 23
• Making Antibodies Rapidly to Respond to Pandemic Outbreaks
WEDNESDAY
Week 1: June 3
• Antibodies for Cancer Therapy
Week 2: June 10
• Clinical Progress of Bispecifics and Combinations
Week 3: June 17
• Advances in Cell-Based Immunotherapy
Week 4: June 24
• Next-Generation Immunotherapies
THURSDAY
Week 1: June 4
• Characterization for Novel Biotherapeutic Modalities
Week 2: June 11
• Novel Biophysical Methods
Week 3: June 18
• Cell and Gene Therapy Analytics
Week 4: June 25
• Rapid Lead Selection and Developability Analysis
FRIDAY
Week 1: June 5
• Difficult-to-Express Proteins
Week 2: June 12
• Protein Production Strategies
Week 3: June 19
• Optimizing Protein Expression
Week 4: June 26
• Engineering Expression Systems
Keynote Speakers Include
Imre Berger, PhD
Director, Max Planck Centre for Minimal Biology, the University of Bristol
Adrian Bot, PhD
Vice President, Translational Medicine, Kite Pharma, a Gilead Company
Daniel Chen, MD, PhD
CMO, IGM Biosciences
Ivan Correia, MBA, PhD
Head, Global Protein Sciences, AbbVie
Zhimei Du, PhD
Director, Process Development, Merck and Co., Inc.
Stefan Dübel, PhD
Professor & Chair, Technische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics
Mitchell Ho, PhD
Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH
Jacob Glanville, PhD
Co-Founder & CEO & President, Distributed Bio Inc.
Jonathan Kingsbury, PhD
Senior Director, Developability & Preformulation Science, Sanofi
Christian Klein, PhD
Cancer Immunotherapy Discovery, Roche Pharma Research & Early Development, Roche Innovation Center Zurich
David Lowe, PhD
Senior Director, R&D, Antibody Discovery and Protein Engineering, AstraZeneca
Jan Joseph Melenhorst, PhD
Adjunct Associate Professor, Pathology & Laboratory Medicine, University of Pennsylvania
Raymond J. Owens, PhD
Professor, Research Complex at Hartwell & Rosalind Franklin Institute, University of Oxford
Paul Parren, PhD
Executive Vice President, Head, R&D, Lava Therapeutics B.V.
Rana Sidhu, PhD
Protein Expression Lead, Early Solutions, UCB, Inc.
Peter Tessier, PhD
Professor, Pharmaceutical Sciences and Chemical Engineering, University of Michigan
Premier Sponsor
Corporate Sponsors
